title: The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers.
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Mitchell
authors.forename: Howard L
authors.initials: HL
authors.lastname: Fields
authors.forename: Raymond L
authors.initials: RL
authors.lastname: White
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Meadoff
authors.forename: Geoff
authors.initials: G
authors.lastname: Joslyn
authors.forename: Michael C
authors.initials: MC
authors.lastname: Rowbotham
mesh_terms: D000328:Adult; D000437:Alcoholism / Q000235:genetics* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D009271:Naltrexone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D017450:Receptors, Opioid, mu / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D009292:Narcotic Antagonists; D017450:Receptors, Opioid, mu; D009271:Naltrexone